Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 12/20 | 0.75 |
| ▸ | PRKCI | P41743 | 1/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | GRM5 | P41594 | 1/20 | 0.62 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.61 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.61 |
| ▸ | CDK2 | P24941 | 2/20 | 0.61 |
| ▸ | GSK3B | P49841 | 2/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | PRKDC | P78527 | 1/20 | 0.55 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.55 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL559881 | 0.86 | ATR (1.00) | ATRCYP3A4GRM5PRKDC | |
| SCHEMBL12518638 | 0.85 | PRKCI (0.69) | ATRPRKCICYP3A4CCNE2CCNE1 | |
| SCHEMBL14059993 | 0.85 | ATR (0.76) | ATRPRKCICYP3A4GRM5PRKDC | |
| SCHEMBL31387927 | 0.85 | ATR (0.76) | ATRPRKCICYP3A4GRM5PRKDC | |
| SCHEMBL15724439 | 0.82 | ATR (0.68) | ATRPRKCICYP3A4GRM5PRKDC | |
| SCHEMBL6615544 | 0.82 | ATR (0.88) | ATRCYP3A4CCNE2CCNE1CDK2 | |
| SCHEMBL6616649 | 0.81 | HDAC6 (0.60) | ATRPRKCICYP3A4CCNE2CCNE1 | |
| SCHEMBL6616616 | 0.80 | ATR (0.78) | ATRCYP3A4CCNE2CCNE1CDK2 | |
| SCHEMBL560472 | 0.80 | ATR (0.69) | ATRPRKCICYP3A4CCNE2CCNE1 | |
| Hydrochloric Acid SCHEMBL6617983 | 0.79 | ATR (0.77) | ATRCYP3A4CCNE2CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4674088-B2 | — | — | 2011-04-20 | — | — | JP | claimed |
| EP-2161265-A2 | Compounds having selective inhibiting effect at GSK3 | Astra Zeneca AB (SE) | 2010-03-10 | — | — | EP | claimed |
| US-20060173014-A1 | Nobel compounds having selective inhibiting effect at gsk3 | ASTRAZENECA AB (SE) | 2006-08-03 | — | — | US | claimed |
| US-20060116362-A1 | Nobel compounds having selective inhibiting effect at gsk3 | ASTRAZENECA AB (SE) | 2006-06-01 | — | — | US | claimed |
| JP-2006513180-A | — | — | 2006-04-20 | — | — | JP | claimed |
| US-20060052396-A1 | Arylamines for the treatment of conditions associated with gsk-3 | ASTRAZENECA (SE) | 2006-03-09 | — | — | US | claimed |
| EP-1575939-A1 | NOVEL COMPOUNDS HAVING SELECTIVE INHIBITING EFFECT AT GSK3 | AstraZeneca AB (SE) | 2005-09-21 | — | — | EP | claimed |
| EP-1575938-A1 | NOVEL COMPOUNDS HAVING SELECTIVE INHIBITING EFFECT AT GSK3 | AstraZeneca AB (SE) | 2005-09-21 | — | — | EP | claimed |
| CN-1551869-A | Novel compound | — | 2004-12-01 | — | — | CN | claimed |
| US-20040186113-A1 | Heterocyclic amines for the treatment of conditions associated with gsk-3 | ASTRAZENECA AB (SE) | 2004-09-23 | — | — | US | claimed |
| WO-2004055005-A1 | NOVEL COMPOUNDS HAVING SELECTIVE INHIBITING EFFECT AT GSK3 | ASTRAZENECA AB (SE) | 2004-07-01 | — | — | WO | claimed |
| WO-2004055006-A1 | NOVEL COMPOUNDS HAVING SELECTIVE INHIBITING EFFECT AT GSK3 | ASTRAZENECA AB (SE) | 2004-07-01 | — | — | WO | claimed |
| EP-1414801-A1 | ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | AstraZeneca AB (SE) | 2004-05-06 | — | — | EP | claimed |
| EP-1406877-A1 | HETEROCYCLIC AMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | AstraZeneca AB (SE) | 2004-04-14 | — | — | EP | claimed |
| WO-2003004472-A1 | ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | WO | claimed |
| WO-2003004475-A1 | HETEROCYCLIC AMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | WO | claimed |
| CN-113248473-B | Preparation and medical application of targeted GSK3 alpha/beta degradation agent | 中国药科大学 | 2022-02-18 | — | — | CN | disclosed |
| CN-113248473-A | Preparation and medical application of targeted GSK3 alpha/beta degradation agent | 中国药科大学 | 2021-08-13 | — | — | CN | disclosed |
| WO-2003004472-A1 | ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | WO | disclosed |
| WO-2003004475-A1 | HETEROCYCLIC AMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116362-A1 | Nobel compounds having selective inhibiting effect at gsk3 | GSK3B, GSK3A, CSNK1A1L | ATR 2350/4885PRKCI 406/4885CYP3A4 1112/4885 |
| US-20040186113-A1 | Heterocyclic amines for the treatment of conditions associated with gsk-3 | GSK3A, GSK3B, PYGL | ATR 1381/4885PRKCI 851/4885CYP3A4 1187/4885 |
| US-20060173014-A1 | Nobel compounds having selective inhibiting effect at gsk3 | GSK3B, GSK3A, GSKIP | ATR 721/4885PRKCI 128/4885CYP3A4 2552/4885 |
| US-20060052396-A1 | Arylamines for the treatment of conditions associated with gsk-3 | GSK3A, GSK3B, PYGL | ATR 1626/4885PRKCI 790/4885CYP3A4 1063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.